Proteogenomic Analysis Identifies Neoantigens and Bacterial Peptides As Immunotherapy Targets in Colorectal Cancer

Pengju Yao,Mingjie Gao,Weiyi Hu,Jiahao Wang,Yuhao Wang,Qingsong Wang,Jianguo Ji
DOI: https://doi.org/10.1016/j.phrs.2024.107209
IF: 10.334
2024-01-01
Pharmacological Research
Abstract:Considerable progress has recently been made in cancer immunotherapy, including immune checkpoint blockade, cancer vaccine, and adoptive T cell methods. The lack of effective targets is a major cause of the low immunotherapy response rate in colorectal cancer (CRC). Here, we used a proteogenomic strategy comprising immunopeptidomics, whole exome sequencing, and 16S ribosomal DNA sequencing analyses of 8 patients with CRC to identify neoantigens and bacterial peptides that can serve as antitumor targets. This study directly identified several personalized neoantigens and bacterial immunopeptides. Immunoassays showed that all neoantigens and 5 of 8 bacterial immunopeptides could be recognized by autologous T cells. Additionally, T cell receptor (TCR) αβ sequencing revealed the TCR repertoire of epitope-reactive CD8+ T cells. Functional studies showed that T cell receptor-T (TCR-T) could be activated by epitope pulsed lymphoblastoid cells. Overall, this study comprehensively profiled the CRC immunopeptidome, revealing several neoantigens and bacterial peptides with potential to serve as immunotherapy targets in CRC.
What problem does this paper attempt to address?